Khan Saifur R, Baghdasarian Argishti, Fahlman Richard P, Michail Karim, Siraki Arno G
Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Canada.
Department of Biochemistry, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Canada.
Drug Discov Today. 2014 May;19(5):562-78. doi: 10.1016/j.drudis.2013.11.001. Epub 2013 Nov 8.
In drug discovery and development (DDD), the efficacy, safety and cost of new chemical entities are the main concerns of the pharmaceutical industry. Continuously updated and stricter recommendations imposed by regulatory authorities result in greater challenges being faced by the industry. Reliable high-throughput techniques integrated with well-designed analytical tools at all stages of DDD (termed 'next-generation DDD') could be a possible approach to obtaining new drug approval by cutting costs as well as ensuring the highest level of patient safety. In this review, we describe the various components of holistic toxicogenomics with examples of applications, and discuss the various analytical tools and platforms to illustrate the current status and prospects of next-generation DDD.
在药物发现与开发（DDD）中，新化学实体的疗效、安全性和成本是制药行业主要关注的问题。监管机构不断更新且更为严格的建议给该行业带来了更大的挑战。在DDD的各个阶段将可靠的高通量技术与精心设计的分析工具相结合（称为“下一代DDD”），可能是一种既能降低成本又能确保患者安全达到最高水平从而获得新药批准的可行方法。在本综述中，我们通过应用实例描述了整体毒理基因组学的各个组成部分，并讨论了各种分析工具和平台，以阐明下一代DDD的现状和前景。
